Catheter-based renal denervation (RDN) appears to be a cost-effective strategy for resistant hypertension that may lower cardiovascular morbidity and mortality. In a study, recipients of RDN had an average survival of 18.4 years, compared with 17.1 years for those receiving standard care. RDN was associated with lifetime savings of $3,071 per quality-adjusted life-year.

Abstract: Journal of the American College of Cardiology, September 2012.